Oropharyngeal Squamous Cell Carcinoma

Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Cue Biopharma
Cue BiopharmaBOSTON, MA
1 program
1
CUE-101Phase 21 trial
Active Trials
NCT04852328Recruiting30Est. Oct 2027
Precision BioSciences
1 program
Pre-Radiation Dental Evaluation/Sample CollectionN/A1 trial
Active Trials
NCT06362421Withdrawn0Est. Aug 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Cue BiopharmaCUE-101
Precision BioSciencesPre-Radiation Dental Evaluation/Sample Collection

Clinical Trials (2)

Total enrollment: 30 patients across 2 trials

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Start: Dec 2021Est. completion: Oct 202730 patients
Phase 2Recruiting
NCT06362421Precision BioSciencesPre-Radiation Dental Evaluation/Sample Collection

Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer

Start: Aug 2025Est. completion: Aug 20260
N/AWithdrawn

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 30 patients
2 companies competing in this space